13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001056807
Total reported value
$3.9B
$3.9B
60 檔
42.0%
As reported in its official Q2 2024 Form 13F filing, Bvf Inc/il's tracked investment portfolio stood at $3.9B with 60 total positions.
During Q2 2024, Bvf Inc/il's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including MLTX, RVMD, KYMR) accounted for 42.0% of total reported equity market value during Q2 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 26.81% | -1.53% | — | |
| 2 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 6.51% | +5.35% | — | |
| 3 | KYMR | Kymera Therapeutics Inc | Stock-Other | 4.32% | -3.25% | — | |
| 4 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 4.26% | — | +31.20% | |
| 5 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 4.19% | -1.50% | — | |
| 6 | GHRS | GH Research PLC | Stock-Other | 3.40% | +2.08% | — | |
| 7 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 3.22% | — | -11.63% | |
| 8 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 2.81% | +0.08% | +79.89% | |
| 9 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 2.77% | -0.83% | — | |
| 10 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.74% | -0.69% | +206.00% | |
| 11 | XOMA | Xoma Royalty Corporation | Stock-Other | 2.41% | +5.66% | — | |
| 12 | KURA | Kura Oncology Inc | Stock-Other | 2.36% | +0.18% | -14.71% | |
| 13 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 2.31% | +0.13% | — | |
| 14 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 2.15% | — | — | |
| 15 | CGON | Cg Oncology Inc | Stock-Other | 2.14% | — | +28.32% | |
| 16 | ✓ | Merus N V | Stock-Other | 2.12% | — | +9.11% | |
| 17 | ACIU | AC Immune SA | Stock-Other | 2.11% | -0.53% | +29.26% | |
| 18 | TYRA | Tyra Biosciences Inc | Stock-Other | 2.09% | -1.20% | — | |
| 19 | ETNBGBP | 89bio Inc | Stock-Other | 1.70% | — | +87.00% | |
| 20 | CELC | Celcuity Inc | Stock-Other | 1.59% | — | — | |
| 21 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.59% | — | — | |
| 22 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.44% | — | — | |
| 23 | ZYME | Zymeworks Inc | Stock-Other | 1.40% | -0.54% | — | |
| 24 | EPIEUR | Essa Pharma Inc | Stock-Other | 1.29% | — | — | |
| 25 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.14% | — | — | |
| 26 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 1.09% | — | -15.79% | |
| 27 | ANNX | Annexon Inc | Stock-Other | 0.96% | -0.27% | — | |
| 28 | RPTX | Repare Therapeutics Inc | Stock-Other | 0.96% | — | — | |
| 29 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.85% | -0.16% | — | |
| 30 | ✓ | Stock-Other | 0.82% | — | — | ||
| 31 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.82% | — | — | |
| 32 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.81% | — | — | |
| 33 | ✓ | Engene Holdings Inc | Stock-Other | 0.59% | — | — | |
| 34 | JANX | Janux Therapeutics Inc | Stock-Other | 0.52% | — | -84.88% | |
| 35 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.49% | -0.04% | — | |
| 36 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.47% | +0.01% | +45.45% | |
| 37 | ALLKGUSD | Allakos Inc | Stock-Other | 0.46% | — | — | |
| 38 | VTLUSD | Immunic Inc | Stock-Other | 0.28% | -0.27% | EXIT | |
| 39 | ✓ | Ikena Oncology Inc | Stock-Other | 0.22% | — | — | |
| 40 | VIGL | Vigil Neuroscience Inc | Stock-Other | 0.20% | — | — | |
| 41 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.20% | — | — | |
| 42 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.18% | — | -20.73% | |
| 43 | ✓ | Elevation Oncology Inc | Stock-Other | 0.17% | — | — | |
| 44 | VSTM | Verastem Inc | Stock-Other | 0.14% | — | — | |
| 45 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.11% | — | — | |
| 46 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.09% | — | — | |
| 47 | MOLN | Molecular Partners AG -adr | Stock-Other | 0.09% | -0.04% | — | |
| 48 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.08% | — | — | |
| 49 | SABS | Sab Biotherapeutics Inc | Stock-Other | 0.08% | — | — | |
| 50 | GLYCEUR | Glycomimetics Inc | Stock-Other | 0.08% | — | — |
According to official SEC Form 13F filings, Bvf Inc/il reported a total U.S. public equity portfolio value of $3.9B across 60 disclosed positions in Q2 2024.
During Q2 2024, Bvf Inc/il's top holdings by market value included MLTX (26.8%)、RVMD (6.5%)、KYMR (4.3%). The largest single position, MLTX, represented 26.8% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q2 2024, Bvf Inc/il made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.